Eli Lilly and Company

20 registered trials on this site, 5 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.

Compounds covered

Registered trials

Trial	Compound	Phase	Status	Sponsor	Enrolled	Primary completion	Registry updated
A Study of LY3537031 in Overweight, Obese, and Healthy Participants NCT06606106	Brenipatide	Phase 1	Active not recruiting	Eli Lilly and Company	302	Nov 2026	Sep 30, 2026
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571	Eloralintide	Phase 2	Completed	Eli Lilly and Company	367	Jul 1, 2026	Sep 29, 2026
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder NCT07219966	Brenipatide	Phase 3	Recruiting	Eli Lilly and Company	1,100	Apr 2028	Sep 22, 2026
A Study of Brenipatide in Participants With Alcohol Use Disorder NCT07219953	Brenipatide	Phase 3	Recruiting	Eli Lilly and Company	1,100	Apr 2028	Sep 22, 2026
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide NCT06897475	Nisotirostide	Phase 2	Recruiting	Eli Lilly and Company	200	May 2027	Sep 14, 2026
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight NCT07808060	Eloralintide	Phase 1	Not yet recruiting	Eli Lilly and Company	34	Jun 2027	Sep 8, 2026
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight NCT05929066	Retatrutide	Phase 3	Completed	Eli Lilly and Company	2,335	Apr 6, 2026	Aug 21, 2026
A Study of Brenipatide in Adult Participants With Major Depressive Disorder NCT07412756	Brenipatide	Phase 3	Recruiting	Eli Lilly and Company	1,000	Feb 2028	Aug 6, 2026
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese NCT05616013	Bimagrumab	Phase 2	Completed	Eli Lilly and Company	507	May 16, 2024	Jul 8, 2026
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight NCT06230523	Eloralintide	Phase 2	Completed	Eli Lilly and Company	263	May 30, 2025	Jun 24, 2026
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415	Retatrutide	Phase 3	Active not recruiting	Eli Lilly and Company	600	Oct 2028	Jun 9, 2026
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728	Bimagrumab	Phase 2	Active not recruiting	Eli Lilly and Company	252	Jan 16, 2026	May 26, 2026
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) NCT06354660	Retatrutide	Phase 3	Completed	Eli Lilly and Company	537	Jan 22, 2026	Mar 5, 2026
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee NCT05931367	Retatrutide	Phase 3	Completed	Eli Lilly and Company	445	Nov 14, 2025	Jan 21, 2026
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05936151	Retatrutide	Phase 2	Completed	Eli Lilly and Company	146	Oct 1, 2025	Nov 25, 2025
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes NCT06901349	Bimagrumab	Phase 2	Withdrawn	Eli Lilly and Company	–	Jun 10, 2025	Sep 24, 2025
A Study of LY3841136 in Healthy and Overweight Participants NCT05295940	Eloralintide	Phase 1	Completed	Eli Lilly and Company	148	Jan 25, 2024	Apr 1, 2024
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight NCT04881760	Retatrutide	Phase 2	Completed	Eli Lilly and Company	338	May 16, 2022	Sep 13, 2023
A Study of LY3457263 in Obese Participants NCT05582096	Nisotirostide	Phase 1	Completed	Eli Lilly and Company	38	Jun 8, 2023	Jul 18, 2023
A Study of LY3437943 in Participants With Type 2 Diabetes NCT04867785	Retatrutide	Phase 2	Completed	Eli Lilly and Company	281	Jul 8, 2022	Jul 3, 2023

Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.

Eli Lilly and Company

Eli Lilly and Company

Compounds covered

Registered trials

Explore

Beginner guides

Research areas

Tools and pipeline